Quarterly ResultMay 6, 2026, 06:14 AM
BeOne Medicines Q1 Revenue +35% to $1.51B; Diluted GAAP EPS $1.96
AI Summary
BeOne Medicines Ltd. announced strong first-quarter 2026 financial results, with total global revenues increasing 35% year-over-year to $1.51 billion, driven by a 38% rise in BRUKINSA global sales to $1.1 billion. The company reported diluted GAAP EPS of $1.96 and non-GAAP diluted EPS of $3.24. BeOne also updated its full-year 2026 revenue guidance to a range of $6.3 billion to $6.5 billion and highlighted significant clinical and regulatory advancements, including US FDA Priority Review for TEVIMBRA and the commercial launch of Sonrotoclax in China.
Key Highlights
- Total global revenues for Q1 2026 were $1.51 billion, an increase of 35% from prior year.
- BRUKINSA global revenues reached $1.1 billion, up 38% year-over-year.
- Diluted GAAP Earnings per ADS were $1.96; non-GAAP diluted Earnings per ADS were $3.24.
- Full Year 2026 total revenue guidance updated to $6.3 billion - $6.5 billion.
- TEVIMBRA sBLA accepted by US FDA with Priority Review for first-line HER2-positive GEA.
- Sonrotoclax launched commercially in China for R/R MCL and R/R CLL/SLL.
- Entered exclusive option with Huahui Health to license HH160 (BON-110) trispecific antibody.